Positive Phase 3 results from the INTerpath-001 trial, showing a 42% reduction in melanoma recurrence or death when the personalized mRNA vaccine intismeran autogene (mRNA-4157/V940) was added to Keytruda, have driven strong trader consensus on a timely BLA submission. Moderna and Merck announced the data in August 2026, released detailed findings in October at ESMO, and confirmed they are actively engaging regulators with an eye toward filing in late 2026 or early 2027. This timeline, combined with the vaccine’s Breakthrough Therapy Designation and the companies’ stated 2027 launch target, supports the market-implied odds near 87% for submission by June 30, 2027. Key upcoming catalysts include any official filing announcement or FDA acceptance, which would further solidify the outcome while leaving modest room for typical manufacturing or review delays.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano1H6H1D7D30DALL
View resolved

Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania